Bioinformatics, chemoinformatics, and pharmainformatics analysis of HER2/HSP90 dual-targeted inhibitors

Journal of the Taiwan Institute of Chemical Engineers

Volumn 41, Issue 2, 2010, Pages 143-149

  Chen, Calvin Yu Chian ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

Author keywords

CoMFA; Dual targeted inhibitors; HER2; HSP90; Pharmacophore

Indexed keywords

BENZENE RING; CANCER CELLS; CANCER THERAPY; CHEMOINFORMATICS; COMPARATIVE MOLECULAR FIELD ANALYSIS; CONTOUR MAP; COST DIFFERENCES; CROSS VALIDATION; HEAT SHOCK PROTEIN; HUMAN EPIDERMAL GROWTH FACTOR; PHARMACOPHORE MODELS; PHARMACOPHORES; PREDICTIVE MODELS; SIGNAL PATHWAYS;

BENZENE; BIOINFORMATICS; CELL PROLIFERATION; ENZYME INHIBITION; PROTEINS;

PHARMACODYNAMICS;

EID: 77249097809     PISSN: 18761070     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtice.2009.08.007     Document Type: Article

References (35)

1. Awale M., and Mohan C.G. 3D-QSAR CoMFA Analysis of C5 Substituted Pyrrolotriazines as HER2 (ErbB2) Inhibitors. J. Mol. Graph. Model. 26 (2008) 1169
2. Benvenuti S., and Comoglio P.M. The MET Receptor Tyrosine Kinase in Invasion and Metastasis. J. Cell Physiol. 213 (2007) 316
3. Bolognesi M.L., Cavalli A., Valgimigli L., Bartolini M., Rosini M., Andrisano V., Recanatini M., and Melchiorre C. Multi-target-directed Drug Design Strategy: From a Dual Binding Site Acetylcholinesterase Inhibitor to a Trifunctional Compound Against Alzheimer's Disease. J. Med. Chem. 50 (2007) 6446
4. Bush B.L., and Nachbar Jr. R.B. Sample-distance Partial Least Squares: PLS Optimized for many Variables, with Application to CoMFA. J. Comput. Aided Mol. Des. 7 (1993) 587
5. Calderwood S.K., Khaleque M.A., Sawyer D.B., and Ciocca D.R. Heat Shock Proteins in Cancer: Chaperones of Tumorigenesis. Trends Biochem. Sci. 31 (2006) 164
6. Chen C.Y.C. Discovery of Novel Inhibitors for c-Met by Virtual Screening and Pharmacophore Analysis. J. Chin. Inst. Chem. Eng. 39 (2008) 617
7. Chen C.Y.C. Insights into the Suanzaoren Mechanism-From Constructing the 3D Structure of GABA-A Receptor to its Binding Interaction Analysis. J. Chin. Inst. Chem. Eng. 39 (2008) 663
8. Chen C.Y.C. A Novel Perspective on Designing the Inhibitor of HER2 Receptor. J. Chin. Inst. Chem. Eng. 39 (2008) 291
9. Chen C.Y.C. Chemoinformatics and Pharmacoinformatics Approach for Exploring the GABA-A Agonist from Chinese Herb Suanzaoren. J. Taiwan Inst. Chem. Eng. 40 (2009) 36
10. Chen C.Y.C. De novo Design of Novel Selective COX-2 Inhibitors: From Virtual Screening to Pharmacophore Analysis. J. Taiwan Inst. Chem. Eng. 40 (2009) 55
11. Chen C.Y.C. Pharmacoinformatics Approach for mPGES-1 in Anti-inflammation by 3D-QSAR Pharmacophore Mapping. J. Taiwan Inst. Chem. Eng. 40 (2009) 155
12. Chen C.Y.C., Chen Y.F., Wu C.H., and Tsai H.Y. What is the Effective Component in Suanzaoren Decoction for Curing Insomnia? Discovery by Virtual Screening and Molecular Dynamic Simulation. J. Biomol. Struct. Dyn. 26 (2008) 57
13. Chen C.Y., Chang Y.H., Bau D.T., Huang H.J., Tsai F.J., Tsai C.H., and Chen C.Y.C. Ligand-based Dual Target Drug Design for H1N1: Swine Flu-A Preliminary First Study. J. Biomol. Struct. Dyn. 27 (2009) 171
14. Chen C.Y., Chang Y.H., Bau D.T., Huang H.J., Tsai F.J., Tsai C.H., and Chen C.Y.C. Discovery of Potent Inhibitors for Phosphodiesterase 5 by Virtual Screening and Pharmacophore Analysis. Acta Pharmacol. Sin. 30 (2009) 1186
15. Chen Y.C., and Chen K.T. Novel Selective Inhibitors of Hydroxyxanthone Derivatives for Human Cyclooxygenase-2. Acta Pharmacol. Sin. 28 (2007) 2027
16. Datar P.A., and Coutinho E.C. A CoMFA Study of COX-2 Inhibitors with Receptor Based Alignment. J. Mol. Graph. Model. 23 (2004) 239
17. de Jonge M.J., and Verweij J. Multiple Targeted Tyrosine Kinase Inhibition in the Clinic: All for One or One for All?. Eur. J. Cancer 42 (2006) 1351
18. De Luca A., Carotenuto A., Rachiglio A., Gallo M., Maiello M.R., Aldinucci D., Pinto A., and Normanno N. The Role of the EGFR Signaling in Tumor Microenvironment. J. Cell Physiol. 214 (2008) 559
19. Ge J., Normant E., Porter J.R., Ali J.A., Dembski M.S., Gao Y., Georges A.T., Grenier L., Pak R.H., Patterson J., Sydor J.R., Tibbitts T.T., Tong J.K., Adams J., and Palombella V.J. Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-soluble Inhibitors of Hsp90. J. Med. Chem. 49 (2006) 4606
20. Gee M.S., Upadhyay R., Bergquist H., Weissleder R., Josephson L., and Mahmood U. Multiparameter Noninvasive Assessment of Treatment Susceptibility, Drug Target Inhibition and Tumor Response Guides Cancer Treatment. Int. J. Cancer 121 (2007) 2492
21. Holden S.N., Eckhardt S.G., Basser R., de Boer R., Rischin D., Green M., Rosenthal M.A., Wheeler C., Barge A., and Hurwitz H.I. Clinical Evaluation of ZD6474, an Orally Active Inhibitor of VEGF and EGF Receptor Signaling, in Patients with Solid, Malignant Tumors. Ann. Oncol. 16 (2005) 1391
22. Immormino R.M., Kang Y., Chiosis G., and Gewirth D.T. Structural and Quantum Chemical Studies of 8-Aryl-sulfanyl Adenine Class Hsp90 Inhibitors. J. Med. Chem. 49 (2006) 4953
23. Kindler H.L., Friberg G., Skoog L., Wade-Oliver K., and Vokes E.E. Phase I/II Trial of Gefitinib and Oxaliplatin in Patients with Advanced Colorectal Cancer. Am. J. Clin. Oncol. 28 (2005) 340
24. Llauger L., He H., Kim J., Aguirre J., Rosen N., Peters U., Davies P., and Chiosis G. Evaluation of 8-Arylsulfanyl, 8-Arylsulfoxyl, and 8-Arylsulfonyl Adenine Derivatives as Inhibitors of the Heat Shock Protein 90. J. Med. Chem. 48 (2005) 2892
25. Nair P.C., and Sobhia M.E. CoMFA Based de Novo Design of Pyridazine Analogs as PTP1B Inhibitors. J. Mol. Graph. Model. 26 (2007) 117
26. Neckers L. Heat Shock Protein 90: The Cancer Chaperone. J. Biosci. 32 (2007) 517
27. Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R., Carotenuto A., De Feo G., Caponigro F., and Salomon D.S. Epidermal Growth Factor Receptor (EGFR) Signaling in Cancer. Gene 366 (2006) 2
28. Obermann W.M., Sondermann H., Russo A.A., Pavletich N.P., and Hartl F.U. In vivo Function of Hsp90 is Dependent on ATP Binding and ATP Hydrolysis. J. Cell Biol. 143 (1998) 901
29. Petrelli A., and Giordano S. From Single- to Multi-target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage. Curr. Med. Chem. 15 (2008) 422
30. Ryan A.J., and Wedge S.R. ZD6474-a Novel Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity. Br. J. Cancer 92 Suppl 1 (2005) S6
31. Stirling P.C., Bakhoum S.F., Feigl A.B., and Leroux M.R. Convergent Evolution of Clamp-like Binding Sites in Diverse Chaperones. Nat. Struct. Mol. Biol. 13 (2006) 865
32. Stravopodis D.J., Margaritis L.H., and Voutsinas G.E. Drug-mediated Targeted Disruption of Multiple Protein Activities Through Functional Inhibition of the Hsp90 Chaperone Complex. Curr. Med. Chem. 14 (2007) 3122
33. Thorogood S.A., Wood P.D., and Prentice G.A. An Evaluation of the Charm Test-A Rapid Method for the Detection of Penicillin in Milk. J. Dairy Res. 50 (1983) 185
34. Vadivelan S., Sinha B.N., Rambabu G., Boppana K., and Jagarlapudi S.A. Pharmacophore Modeling and Virtual Screening Studies to Design Some Potential Histone Deacetylase Inhibitors as New Leads. J. Mol. Graph. Model. 26 (2008) 935
35. Zou J.W., Luo C.C., Zhang H.X., Liu H.C., Jiang Y.J., and Yu Q.S. Three-dimensional QSAR of HPPD Inhibitors, PSA Inhibitors, and Anxiolytic Agents: Effect of Tautomerism on the CoMFA Models. J. Mol. Graph. Model. 26 (2007) 494